Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive ...

Privately-held Alloy Therapeutics has announced a new multi-year collaboration with Pfizer to develop a bespoke platform that ...

Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to­ USD 3.3 billion, implying 1 ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) ...

Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- For over 25 years, the ORBIE® Awards have recognized technology executives for ...

Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...